Marker Therapeutics Financials - Benzinga

Marker Therapeutics Inc

MRKRNASDAQ

Trade with Public

Trade with Public

$1.15

-0.05-4.17%

At close: Sep 11, 5:00 PM EST

$1.28

0.1311.3%

After Hours: Sep 8, 4:02 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Marker Therapeutics Financials

Marker Therapeutics (MRKR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Marker Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate

Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 60 percent increase over losses of $(0.40) per share from

Benzinga Newsdesk

PRO
Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate

Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.47) by 81.68 percent. This is a 79.29 percent increase over losses of $(0.42) per share

Benzinga Newsdesk

PRO
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate

Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.47) by 74.74 percent. This is a 53.85 percent increase over losses of $(0.26) per share

Benzinga Newsdesk

Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings

Avi Kapoor

PRO
Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat

Benzinga Newsdesk

PRO
Marker Therapeutics Q2 2024 GAAP EPS $(0.25) Beats $(0.43) Estimate, Sales $1.17M Up From $762.66K YoY

Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.43) by 41.86 percent. The company reported $1.17 million in sales this quarter. This is a

Benzinga Newsdesk